Clinical Trials

At Array BioPharma, we seek to support patients and caregivers by providing clear, up-to-date, accessible information about our products in development. Accordingly, we provide these links to active clinical trials for patients and their caregivers.

Binimetinib (MEK162)

Trial Data
Trial Title
Program: Binimetinib (MEK162)
Phase: 3
Status: Active, not recruiting
Disease: BRAF V600 mutant melanoma
Sponsor: Array BioPharma
Trial Information: NCT01909453
Trial Title: Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma (COLUMBUS)
Program: Binimetinib (MEK162)
Phase: 3
Status: Recruiting
Disease: BRAF-mutant colorectal cancer
Sponsor: Array BioPharma
Trial Information: Learn More
Trial Title: Study evaluating the efficacy and safety of binimetinib, encorafenib and Erbitux in BRAFm metastatic CRC (BEACON CRC)
Program: Binimetinib (MEK162)
Trial Information: ClinicalTrials.gov
Trial Title: Other clinical Trials

Encorafenib (LGX818)

Trial Data
Trial Title
Program: Encorafenib (LGX818)
Phase: 3
Status: Active, not recruiting
Disease: BRAF V600 mutant melanoma
Sponsor: Array BioPharma
Trial Information: NCT01909453
Trial Title: Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma (COLUMBUS)
Program: Encorafenib (LGX818)
Phase: 3
Status: Recruiting
Disease: BRAF-mutant colorectal cancer
Sponsor: Array BioPharma
Trial Information: Learn More
Trial Title: Study evaluating the efficacy and safety of binimetinib, encorafenib and Erbitux in BRAFm metastatic CRC (BEACON CRC)
Program: Encorafenib (LGX818)
Disease:
Sponsor:
Trial Information: ClinicalTrials.gov
Trial Title: Other clinical Trials

Selumetinib (AZD6244)

Trial Data
Trial Title
Program: Selumetinib (AZD6244)
Phase: 3
Status: Recruiting
Disease: Thyroid cancer
Sponsor: AstraZeneca
Trial Information: NCT01843062
Trial Title: Study Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer (ASTRA)
Program: Selumetinib (AZD6244)
Phase: 2
Status: Recruiting
Disease: Neurofibromatosis Type 1
Sponsor: National Cancer Institute
Trial Information: NCT01362803
Trial Title: AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
Program: Selumetinib (AZD6244)
Trial Information: ClinicalTrials.gov
Trial Title: Other clinical trials

ARRY-797

Trial Data
Trial Title
Program: ARRY-797
Phase: 2
Status: Active, not recruiting
Disease: LMNA-related dilated cardiomyopathy
Sponsor: Array
Trial Information: NCT02057341
Trial Title: A Study of ARRY-371797 in Patients with LMNA-Related Dilated Cardiomyopathy

ARRY-382

Trial Data
Trial Title
Program: ARRY-382
Phase: 1
Status: Recruiting
Disease: Solid tumors
Sponsor: Array BioPharma
Trial Information: NCT02880371
Trial Title: A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors

Filanesib (ARRY-520)

Trial Data
Trial Title
Program: Filanesib (ARRY-520)
Phase: 1
Status: Active, not recruiting
Disease: Relapsed/refractory multiple myeloma
Sponsor: M.D. Anderson Cancer Center
Trial Information: NCT01372540
Trial Title: ARRY-520 + Carfilzomib for Multiple Myeloma

ONT-380 (ARRY-380)

Trial Data
Trial Title
Program: ARRY-380 (ONT-380)
Phase: 1b
Status: Active, not recruiting
Disease: Brain metastases from HER2+ breast cancer
Sponsor: Dana-Farber Cancer Institute
Trial Information: NCT01921335
Trial Title: Phase I Dose-escalation Trial of ARRY-380 in Combination With Trastuzumab in Participants With Brain Metastases From HER2+ Breast Cancer
Program: ARRY-380 (ONT-380)
Phase: 1b
Status: Active, not recruiting
Disease: HER2+ breast cancers
Sponsor: Cascadian Therapeutics
Trial Information: NCT02025192
Trial Title: A Phase 1b Study of ONT-380 Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer
Program: ARRY-380 (ONT-380)
Phase: 1b
Status: Active, not recruiting
Disease: HER2+ breast cancers
Sponsor: Cascadian Therapeutics
Trial Information: NCT01983501
Trial Title: A Phase 1b Study of ONT-380 Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer

Other Programs

Trial Data
Trial Title
Program: Ipatasertib (GDC-0068)
Phase: 2
Disease: Solid tumors
Sponsor: Genentech
Trial Information: ClinicalTrials.gov
Trial Title: Clinical trials
Program: LOXO-101
Phase: 2
Status: Recruiting
Disease: Solid tumors
Sponsor: Loxo Oncology
Trial Information: NCT02576431
Trial Title: Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)
Program: Motolimod / VTX2337
Phase: 2
Disease: Solid tumors
Sponsor: VentiRx
Trial Information: ClinicalTrials.gov
Trial Title: Clinical trials
Program: Danoprevir
Phase: 2
Disease: Hepatitis C
Sponsor: Roche
Trial Information: ClinicalTrials.gov
Trial Title: Clinical trials
Program: GDC-0575
Phase: 1
Status: Active, not recruiting
Disease: Lymphoma, Solid tumors
Sponsor: Genentech
Trial Information: NCT01564251
Trial Title: A Study of GDC-0575 Alone And in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
Program: LY2606368
Phase: 2
Status: Recruiting
Disease: Solid tumors
Sponsor: Eli Lilly
Trial Information: ClinicalTrials.gov
Trial Title: Clinical Trials
Program: GDC-0994
Phase: 1
Status: Active, not recruiting
Disease: Solid tumors
Sponsor: Genentech
Trial Information: NCT01875705
Trial Title: A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors